When a patient faces esophageal squamous cell carcinoma, the goal of treatment is to shrink the tumor and clear it during surgery. New data suggests that adding an immune checkpoint inhibitor—a drug that helps the immune system recognize and attack cancer cells—to chemotherapy before surgery can make a big difference. This combination, known as neoadjuvant chemoimmunotherapy, showed much higher rates of major pathological response compared to chemotherapy alone.
In a study of 1,070 patients, those receiving the combined treatment saw a 42.8% major pathological response rate, while those on chemotherapy alone had a 22.2% rate. The results also showed that more patients underwent surgery and had more lymph nodes removed when they received the dual treatment. While some improvements in overall survival and clear surgical margins were noted, these specific findings were only borderline statistically significant.
There is a trade-off to consider regarding safety. Patients receiving the immune therapy were much more likely to experience immune-related adverse events compared to those on chemotherapy alone. However, the number of severe side effects was similar between both groups. Because some data points were less reliable due to differences in how studies were conducted, patients should discuss these specific results and potential side effects with their oncology team.
